gallium maltolate
Small moleculeexperimental
Gallium maltolate is a coordination complex consisting of a trivalent gallium cation coordinated to three maltolate ligands. The compound is a potential therapeutic agent for cancer, infectious disease, and inflammatory disease. A cosmetic skin cream containing gallium maltolate is marketed under the name Gallixa. It is a colorless solid with significant solubility in both water and lipids. — Wikipedia
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2001 (NCT00050687)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- SerotransferrinINHIBITOR
TF inhibitor
Chemistry & pharmacology
- Mol. weight
- 445.03 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGallium maltolate ↗
- ChEMBLCHEMBL6068513 ↗
Also known as
- gallium maltolate
- gallium maltolate
- gallium maltolate
- gallium maltolate
- tris(3-hydroxy-2-methyl-4h-pyran-4-onato)gallium(iii)
- tris(maltolato)gallium(iii)
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04319276 | Phase 1 | Jul 31, 2020 | Medical College of Wisconsin |
| NCT00050687 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2001 | Titan Pharmaceuticals |
| NCT06404034 | N/A | — | Imaging Biometrics, LLC, xCures |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Imaging Biometrics, LLC | For profit | 1 | 1 | 1 | — |
| Medical College of Wisconsin | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Titan Pharmaceuticals | For profit | 1 | 1 | 1 | 2001 |
| xCures | For profit | 1 | 0 | 1 | — |
4 organizations
Page 1 / 1